CRYZL2P-SEC16B

Across TCGA pan-cancer cohorts, CRYZL2P-SEC16B RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of CRYZL2P-SEC16B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CRYZL2P-SEC16B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CRYZL2P-SEC16B is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

KIRC, KICH, and BRCA are the cancer types where CRYZL2P-SEC16B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CRYZL2P-SEC16B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.484	<.001	11	view →
KICH	Female	All	−0.429	<.001	7	view →
BRCA	All	III,IV	−0.279	<.001	6	view →
HNSC	All	II,III,IV	+0.088	.001	6	view →
STAD	All	II,III,IV	+0.288	.013	5	view →
COAD	All	All	+0.191	.005	5	view →
READ	All	All	+0.607	.033	2	view →
LIHC	All	All	+0.313	<.001	2	view →
LUSC	All	II,III,IV	−0.098	.009	2	view →
LUAD	Male	III,IV	−0.118	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

CRYZL2P-SEC16B–KIRC

Open the KIRC breakdown →